Sign in

You're signed outSign in or to get full access.

Brian Flornes

Independent Director at American Healthcare REIT
Board

About Brian J. Flornes

Independent director of American Healthcare REIT (AHR) since February 2016; age 61; member of the Audit Committee and current chairman of the Nominating & Corporate Governance (NCG) Committee. Former co-founder and CEO of Vintage Senior Living with 30+ years operating, acquiring, developing, and financing senior housing; B.A. (Communication) and M.B.A. from Loyola Marymount University; member of the World Presidents’ Organization. The proxy notes his specialized experience in healthcare real estate and senior housing operations as core credentials for AHR’s board.

Past Roles

OrganizationRoleTenureCommittees/Impact
Vintage Senior LivingCo-Founder; Co-CEO (1998–Jun 2010); CEO (Jun 2010–Sep 2018)1998–2018Led acquisition/development/financing of 8,000+ senior living units across 11 states
Joint Venture with major U.S. pension fund (senior living)JV lead/partnerSince Feb 2006Acquired 19 communities; NAV >2.5x invested capital
AHR Special CommitteeMemberOct 2020–Oct 2021Oversight on special/conflict matters

External Roles

OrganizationRoleTenureNotes
American Senior Housing AssociationMember (past)Not disclosedIndustry association participation
California Assisted Living AssociationBoard member (past)Not disclosedSector advocacy/standards
World Presidents’ OrganizationMemberNot disclosedExecutive leadership network

Board Governance

ItemDetail
IndependenceDetermined independent under NYSE rules; AHR has a majority-independent board; committees (Audit, Compensation, NCG) fully independent
CommitteesAudit Committee (member); NCG Committee (Chair)
Committee activityAudit Committee held 5 meetings in 2024; NCG Committee held 3 meetings in 2024
Board meetings & attendanceBoard held 9 meetings in 2024; each incumbent director attended at least 75% of aggregate Board and committee meetings served
Annual meeting attendanceAll directors attended the most recent annual meeting
Lead independent directorAHR does not maintain a lead independent director (non-management executive sessions are presided over by the non-executive Chair)
NCG Chair start date (note)Director bio states NCG Chair since Oct 2021; committee section states since June 2023 (proxy contains both references)
Governance policiesCorporate Governance Guidelines; Code of Ethics; Whistleblower; Insider Trading Policy; Clawback; Related Party Transactions Policy
Conflicts oversightNCG oversees conflicts and related-party matters; directors with interests recuse from related-party votes

Fixed Compensation (Director pay)

Element2024 Amount
Fees Earned or Paid in Cash$102,500 (reflects committee roles)
All Other Compensation$21,923 (distributions on stock awards)
Total Director Compensation$316,582 (cash + equity fair value + distributions)

Director cash fee schedule (2024): Audit Committee: Chair $20,000; Member $5,000. Compensation Committee: Chair $12,500. Nominating & Corporate Governance Committee: Chair $12,500. Lead Independent Director: $100,000. (Independent directors reimbursed for meeting expenses.)

Performance Compensation (Equity and vesting)

Grant/InstrumentGrant DateShares/UnitsGrant-Date Fair ValueVestingNotes
Listing Equity Award (restricted stock)Feb 9, 20247,407 shares (to each non-employee director other than CEO/Director Prosky)Included in 2024 “Stock Awards” $192,15925% on each of the first four anniversaries of 2/9/2024 (service-based)Director equity aligns with shareholders; no performance-based director equity disclosed
Nonvested restricted common stock (as of 12/31/2024)11,017 sharesAggregate nonvested shares held by each non-employee director, incl. Mr. Flornes

Notes: AHR’s executive PSU program uses 3-year relative TSR vs. a healthcare REIT peer set; no performance-conditioned equity is disclosed for directors. Hedging and pledging of AHR securities are prohibited by policy.

Other Directorships & Interlocks

CategoryDetail
Current public company boardsNone disclosed for Mr. Flornes
Prior public company boardsNone disclosed for Mr. Flornes
Non-profit/industry boardsCalifornia Assisted Living Association (past); American Senior Housing Association member
Interlocks with competitors/suppliers/customersNone disclosed

Expertise & Qualifications

  • Senior housing operations, real estate acquisition/development/financing, and healthcare real estate domain expertise (30+ years).
  • Education: B.A. (Communication) and M.B.A., Loyola Marymount University.
  • Executive network: World Presidents’ Organization.

Equity Ownership

MetricValue
Beneficial ownership (common) as of Mar 27, 202527,384 shares (<1.0%)
OP UnitsNone
Shares pledgedNone of the disclosed shares have been pledged as security
Ownership guidelinesCorporate Governance Guidelines set minimum stock ownership requirements for directors (specific multiples not disclosed)
Hedging/pledging policyHedging and pledging of AHR securities prohibited for directors/officers

Governance Assessment

  • Strengths: Independent director with sector-operating depth; chairs NCG (conflict oversight, board refreshment, ESG oversight) and serves on Audit, supporting risk/control oversight. Board/committee independence, clawback policy, and anti-hedging/pledging strengthen alignment and oversight.
  • Attendance/engagement: Board met 9 times in 2024 and Audit/NCG met 5/3 times; all incumbents met at least the 75% attendance threshold and attended the annual meeting—baseline engagement satisfied (individual attendance rates not disclosed).
  • Compensation alignment: 2024 director pay mix tilted to equity (service-vested restricted stock) with multi-year vesting; cash fees reflect committee responsibilities (NCG Chair + Audit member). No director performance-conditioned equity disclosed, which is typical in REITs.
  • Shareholder signals (director elections): Notable withhold in 2024 (For: 37,035,533; Withheld: 36,910,722), improving in 2025 (For: 100,685,107; Withheld: 16,587,419), but still among higher withholds—an investor-sentiment flag to monitor.
  • Say-on-pay support (company-wide): Advisory say-on-pay approved—2024 meeting For: 71,399,556 vs. Against: 1,871,807; 2025 meeting For: 109,297,003 vs. Against: 7,525,316—broad support for pay program.
  • Conflicts/related-party: No related-party transactions disclosed involving Mr. Flornes; RPT oversight sits with NCG with recusal requirements; directors were subject to IPO-related lock-ups in 2024.
  • RED FLAGS: Elevated director withhold in 2024 (improved in 2025 but remains higher than peers); minor inconsistency in proxy regarding NCG chair start date (Oct 2021 vs. June 2023). Monitor future votes and disclosures for clarity.

Appendix: Director Election Vote Detail (Signal Tracking)

YearForWithheldBroker Non-Votes
2024 Annual Meeting (Nov 7, 2024)37,035,533 36,910,722 33,651,003
2025 Annual Meeting (Jun 25, 2025)100,685,107 16,587,419 22,564,319